Posted by Michael Wonder on 16 Apr 2020
FDA grants fast track designation to RemeGen's telitacicept as a treatment for systemic lupus erythematosus
15 April 2020 - RemeGen today announced that the US FDA granted fast track designation for RC18, a novel recombinant TACI-Fc (transmembrane activator and calcium modulator and cyclophilin ligand interactor) fusion protein, for the treatment of systemic lupus erythematosus.
With its novel dual-target mechanism, RC18 shows statistically significant improvement for patients at multiple doses.
RC18 is a novel recombinant TACI-Fc (transmembrane activator and calcium modulator and cyclophilin ligand interactor) fusion protein that was developed to treat auto-immune diseases.
